{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:23Z","timestamp":1793982263982,"version":"4.8.0"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune hemolytic anemia (AIHA) is defined by increased erythrocyte turnover mediated by autoimmune mechanisms. While corticosteroids remain first-line therapy in most cases of warm-antibody AIHA, cold agglutinin disease is treated by targeting the underlying clonal B-cell proliferation or the classical complement activation pathway. Several new established or investigational drugs and treatment regimens have appeared during the last 1-2 decades, resulting in an improvement of therapy options but also raising challenges on how to select the best treatment in individual patients. In severe warm-antibody AIHA, there is evidence for the upfront addition of rituximab to prednisolone in the first line. Novel agents targeting B-cells, extravascular hemolysis, or removing IgG will offer further options in the acute and relapsed\/refractory settings. In cold agglutinin disease, the development of complement inhibitors and B-cell targeting agents makes it possible to individualize therapy, based on the disease profile and patient characteristics. For most AIHAs, the optimal treatment remains to be found, and there is still a need for more evidence-based therapies. Therefore, prospective clinical trials should be encouraged.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1180509","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T04:24:23Z","timestamp":1682310263000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?"],"prefix":"10.3389","volume":"14","author":[{"given":"Sigbj\u00f8rn","family":"Berentsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100648:100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2018.1477132","article-title":"Features of peripheral Cd8(+)Cd57(+) lymphocytes in patients with autoimmune hemolytic anemia","volume":"51","author":"Fatone","year":"2018","journal-title":"Autoimmunity"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.282.6281.2023","article-title":"Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre","volume":"282","author":"Sokol","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1586\/EHM.11.60","article-title":"Classification and therapeutic approaches in autoimmune hemolytic anemia: an update","volume":"4","author":"Michel","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a gimema study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02440.x","article-title":"The spherocytic haemolytic anaemias","volume":"112","author":"Packman","year":"2001","journal-title":"Br J Haematol"},{"key":"B10","article-title":"\u00dcber beziehungen zwischen dem blutserum und den k\u00f6rperzellen","volume":"50","author":"Landsteiner","year":"1903","journal-title":"M\u00fcnch Med Wschr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195101252440401","article-title":"The treatment of acquired hemolytic anemia with adrenocorticotrophic hormone (Acth)","volume":"244","author":"Dameshek","year":"1950","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17217","article-title":"Developing the evidence base for the management of autoimmune haemolytic anaemia (Aiha): the uk experience","volume":"192","author":"Hill","year":"2021","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000405","article-title":"Warm autoimmune hemolytic anemia and the best treatment strategies","volume":"2022","author":"Kuter","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.08.001","article-title":"New therapies for the treatment of warm autoimmune hemolytic anemia","volume":"36","author":"Fattizzo","year":"2022","journal-title":"Transfus Med Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/hemato3040040","article-title":"Cold agglutinin disease: improved understanding of pathogenesis helps define targets for therapy","volume":"3","author":"Berentsen","year":"2022","journal-title":"Hemato"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009516","article-title":"Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review","author":"Jacobs","year":"2023","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003808","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128991","article-title":"Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-Detect igm autoantibodies","volume":"100","author":"Meulenbroek","year":"2015","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.02846.x","article-title":"Severe IgA-mediated auto-immune haemolytic anaemia in a 48-Yr-Old woman","volume":"70","author":"Bardill","year":"2003","journal-title":"Eur J Haematol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1084\/jem.132.6.1207","article-title":"The interaction between human monocytes and red cells. specificity for IgG subclasses and IgG fragments","volume":"132","author":"Abramson","year":"1970","journal-title":"J Exp Med"},{"key":"B24","article-title":"[the clinical implications of IgG subclass in 84 patients with autoimmune hemolytic anemia]","volume":"20","author":"Zhang","year":"1999","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7534\/j.issn.1009-2137.2019.01.032","article-title":"[Correlation of IgG subclass with blood cell parameters in patients with autoimmune hemolytic anemia]","volume":"27","author":"Li","year":"2019","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B26","article-title":"Subclasses of warm autoantibody IgG in patients with autoimmune hemolytic anemia and their clinical implications","volume":"112","author":"Li","year":"1999","journal-title":"Chin Med J (Engl)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic fc engineering - modulation of IgG-associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.158.3808.1582","article-title":"Red cells coated with immunoglobulin G: binding and sphering by mononuclear cells in man","volume":"158","author":"LoBuglio","year":"1967","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-6138-1_10","article-title":"A new test for the detection of weak and incomplete Rh agglutinins","volume":"26","author":"Coombs","year":"1945","journal-title":"Br J Exp Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23218","article-title":"The direct antiglobulin test: a critical step in the evaluation of hemolysis","volume":"87","author":"Zantek","year":"2012","journal-title":"Am J Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0578-9","article-title":"Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity","volume":"91","author":"Barcellini","year":"2010","journal-title":"Int J Hematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2147\/CLEP.S250250","article-title":"Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980-2016","volume":"12","author":"Hansen","year":"2020","journal-title":"Clin Epidemiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: causes and consequences","volume":"18","author":"Fattizzo","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V4.11.1196.1196","article-title":"Acquired hemolytic anemia; the relation of erythrocyte antibody production to activity of the disease; the significance of thrombocytopenia and leukopenia","volume":"4","author":"Evans","year":"1949","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005610","article-title":"Evans Syndrome in adults: an observational multicenter study","volume":"5","author":"Fattizzo","year":"2021","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25574","article-title":"Evans Syndrome in adults - incidence, prevalence, and survival in a nationwide cohort","volume":"94","author":"Hansen","year":"2019","journal-title":"Am J Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.12.004","article-title":"Adult evans\u2019 syndrome","volume":"36","author":"Michel","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.3.820.820","article-title":"Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases","volume":"69","author":"Liesveld","year":"1987","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198202043060507","article-title":"Autoimmune hemolytic anemia with reticulocytopenia and erythroid marrow","volume":"306","author":"Conley","year":"1982","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.1.177.177","article-title":"Two distinct categories of warm autoantibody reactivity with age-fractionated red cells","volume":"63","author":"Branch","year":"1984","journal-title":"Blood"},{"key":"B41","article-title":"Idiopathic acquired autoimmune hemolytic anemia. a review of forty-seven cases treated from 1955 through 1965","volume":"43","author":"Allgood","year":"1967","journal-title":"Am J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03729.x","article-title":"Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism","volume":"118","author":"Pullarkat","year":"2002","journal-title":"Br J Haematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm antibody autoimmune hemolytic anemia in adults: new insights based on single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.10.012","article-title":"Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees","volume":"135","author":"Yusuf","year":"2015","journal-title":"Thromb Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.07.001","article-title":"Venous thromboembolism related to warm autoimmune hemolytic anemia: a case-control study","volume":"14","author":"Lecouffe-Desprets","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207218","article-title":"Venous thromboembolic events during warm autoimmune hemolytic anemia","volume":"13","author":"Audia","year":"2018","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/jcm10010164","article-title":"Infectious complications in autoimmune hemolytic anemia","volume":"10","author":"Giannotta","year":"2021","journal-title":"J Clin Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15757","article-title":"Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia","volume":"20","author":"Fattizzo","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B49","article-title":"Drug therapy of autoimmune hemolytic anemia","volume":"13","author":"Murphy","year":"1976","journal-title":"Semin Hematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(21)00630-5","article-title":"Immune haemolytic disease: the autoimmune haemolytic anaemias","volume":"4","author":"Pirofsky","year":"1975","journal-title":"Clin Haematol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3203137.x","article-title":"Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type","volume":"98","author":"Meyer","year":"1997","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/jcm9123858","article-title":"Difficult cases of autoimmune hemolytic anemia: a challenge for the internal medicine specialist","volume":"9","author":"Fattizzo","year":"2020","journal-title":"J Clin Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.3390\/jcm9124034","article-title":"Rituximab use in warm and cold autoimmune hemolytic anemia","volume":"9","author":"Murakhovskaya","year":"2020","journal-title":"J Clin Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-885228","article-title":"Low-dose rituximab in autoimmune hemolytic anemia: 10 years after","volume":"133","author":"Fattizzo","year":"2019","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221097780","article-title":"Efficacy and safety of cyclosporine a treatment in autoimmune cytopenias: the experience of two Italian reference centers","volume":"13","author":"Fattizzo","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2019.102388","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia","volume":"81","author":"Ho","year":"2020","journal-title":"Blood Cells Mol Dis"},{"key":"B59","first-page":"1","article-title":"The auto-immune haemolytic anaemias: introduction","volume-title":"The haemolytic anaemias","author":"Dacie","year":"1992"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01887.x","article-title":"Clinical immunology of chronic cold agglutinin disease","volume":"63","author":"Ulvestad","year":"1999","journal-title":"Eur J Haematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1965.tb01303.x","article-title":"Exclusive occurrence of K chains in isolated cold haemagglutinins","volume":"2","author":"Harboe","year":"1965","journal-title":"Scand J Haematol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a b-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"key":"B64","first-page":"349","article-title":"Cold agglutinin disease","volume-title":"Who classification of haematolymphoid tumours","author":"Naresh","year":"2022"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108547","article-title":"The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man","volume":"58","author":"Jaffe","year":"1976","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556027","article-title":"Tnt003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.04.002","article-title":"Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease","volume":"55","author":"Berentsen","year":"2018","journal-title":"Semin Hematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719873321","article-title":"Novel insights into the treatment of complement-mediated hemolytic anemias","volume":"10","author":"Berentsen","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00590","article-title":"New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia","volume":"11","author":"Berentsen","year":"2020","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12333:928","article-title":"Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02899-6","article-title":"Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan","volume":"112","author":"Kamesaki","year":"2020","journal-title":"Int J Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04948-y","article-title":"Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the cardinal study","volume":"101","author":"R\u00f6th","year":"2022","journal-title":"Ann Hematol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/trf.16765","article-title":"Wind, if winter comes \u2026 will symptoms be far behind?: exploring the seasonality (or lack thereof) and management of cold agglutinin disease","volume":"62","author":"Patriquin","year":"2022","journal-title":"Transfusion"},{"key":"B76","article-title":"Treatment and prognosis of cold-antibody aiha","volume-title":"The haemolytic anaemias","author":"Dacie","year":"1992"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 cadenza trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective gimema study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin Disease\/Cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (Decade): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1182\/blood-2018-99-119468","article-title":"Inhibition of C3 with apl-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with autoimmune hemolytic anemia (Aiha). 60th annual meeting of the American society of hematology, San Diego, Ca","volume":"132","author":"Grossi","year":"2018","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2012.01.002","article-title":"Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia","volume":"26","author":"Berentsen","year":"2012","journal-title":"Blood Rev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90852-X","article-title":"B-cell neoplasms with homogeneous cold-reacting antibodies (Cold agglutinins)","volume":"72","author":"Crisp","year":"1982","journal-title":"Am J Med"},{"key":"B88","first-page":"296","article-title":"Auto-immune haemolytic anaemia (Aiha): cold-antibody syndromes III: haemolytic anaemia following mycoplasma pneumonia","volume-title":"The haemolytic anaemias","author":"Dacie","year":"1992"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1159\/000208668","article-title":"[Acute autoimmune hemolytic anemia caused by cold antibodies following mycoplasma pneumonia with fatal ending]","volume":"44","author":"Schubothe","year":"1970","journal-title":"Acta Haematol"},{"key":"B90","first-page":"895","article-title":"Mycoplasma pneumoniae pneumonia. experience at a referral center","volume":"140","author":"Linz","year":"1984","journal-title":"West J Med"},{"key":"B91","article-title":"Auto-immune haemolytic anaemia (Aiha): cold-antibody syndromes IV: haemolytic anemia following infectious mononucleosis annd other viral infections","volume-title":"The haemolytic anaemias","author":"Dacie","year":"1992"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16892","article-title":"Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (Covid-19)","volume":"190","author":"Zagorski","year":"2020","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.14740\/jh242w","article-title":"A novel approach for treatment of cold agglutinin syndrome-related severe hemolysis","volume":"5","author":"Tesfaye","year":"2016","journal-title":"J Hematol"},{"key":"B94","article-title":"Ueber paroxysmale h\u00e4moglobinurie","volume":"36","author":"Donath","year":"1904","journal-title":"M\u00fcnchener medizinische Wochenschrift"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830020308","article-title":"Hemolysis by complement and cold-reacting antibodies: time and temperature requirements","volume":"2","author":"Rosse","year":"1977","journal-title":"Am J Hematol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000897","article-title":"Paroxysmal cold hemoglobinuria successfully treated with complement inhibition","volume":"3","author":"Lau-Braunhut","year":"2019","journal-title":"Blood Adv"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01805.x","article-title":"Mixed-type autoimmune hemolytic anemia: differential diagnosis and a critical review of reported cases","volume":"48","author":"Mayer","year":"2008","journal-title":"Transfusion"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-015-0863-y","article-title":"Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia","volume":"128","author":"Kulpa","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12541","article-title":"A phase iii randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the raiha study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00235.x","article-title":"Severe autoimmune hemolytic anemia caused by a warm iga autoantibody directed against the third loop of band 3 (Rbc anion-exchange protein 1)","volume":"42","author":"Janvier","year":"2002","journal-title":"Transfusion"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1159\/000366244","article-title":"The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia","volume":"41","author":"Salama","year":"2014","journal-title":"Transfus Med Hemother"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1986.tb01967.x","article-title":"Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin","volume":"51","author":"Bussel","year":"1986","journal-title":"Vox Sang"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","article-title":"Fcrn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1515\/med-2016-0068","article-title":"Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia","volume":"11","author":"Giudice","year":"2016","journal-title":"Open Med (Wars)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015508","article-title":"Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias","volume":"140","author":"Pincez","year":"2022","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.amjsurg.2012.05.030","article-title":"Outcomes and complications after splenectomy for hematologic disorders","volume":"204","author":"Patel","year":"2012","journal-title":"Am J Surg"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03849.x","article-title":"Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study","volume":"8","author":"Thomsen","year":"2010","journal-title":"J Thromb Haemost"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.11.005","article-title":"Updates in the management of warm autoimmune hemolytic anemia","volume":"36","author":"Yui","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"B112","unstructured":"Altered immunocompetence: general best practice guidelines for immunization: best practices guidance of the advisory committee on immunization practices (Acip)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal fcr blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an fcrn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17041","article-title":"Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation","volume":"192","author":"Castleman","year":"2021","journal-title":"Br J Haematol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26508","article-title":"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: phase 2, multicenter, open-label study","volume":"97","author":"Kuter","year":"2022","journal-title":"Am J Hematol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169652","article-title":"Phase 3, randomized, double-blind, placebo-controlled, global study (Forward) of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia","volume":"140","author":"Kuter","year":"2022","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective Pi3kdelta inhibitor, in patients with relapsed or refractory b-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844036.02998.15","article-title":"Long-term efficacy and safety results from an ongoing open-label phase 2 study of parsaclisib for the treatment of autoimmune hemolytic anemia (Aiha)","volume":"6","author":"Barcellini","year":"2022","journal-title":"HemaSphere"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211046428","article-title":"Bortezomib in autoimmune hemolytic anemia and beyond","volume":"12","author":"Pasquale","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia","volume":"187","author":"Fadlallah","year":"2019","journal-title":"Br J Haematol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e28679","DOI":"10.1097\/MD.0000000000028679","article-title":"Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia","volume":"101","author":"Yao","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"B126","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/labmed\/lmw055","article-title":"The challenges of daratumumab in transfusion medicine","volume":"48","author":"Dizon","year":"2017","journal-title":"Lab Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.exphem.2020.08.001","article-title":"Sirolimus is effective for primary Relapsed\/Refractory autoimmune cytopenia: a multicenter study","volume":"89","author":"Li","year":"2020","journal-title":"Exp Hematol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13010","article-title":"Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children","volume":"167","author":"Miano","year":"2014","journal-title":"Br J Haematol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000818","article-title":"Sirolimus as an effective agent in the treatment of immune thrombocytopenia (Itp) and Evans syndrome (Es): a single institution\u2019s experience","volume":"39","author":"Jasinski","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-013-0290-z","article-title":"Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective","volume":"30","author":"Thabet","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404512","article-title":"Treatment of severe refractory autoimmune hemolytic anemia in b-cell chronic lymphocytic leukemia with alemtuzumab (Humanized Cd52 monoclonal antibody)","volume":"21","author":"Karlsson","year":"2007","journal-title":"Leukemia"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-467209","article-title":"C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia","volume":"121","author":"Wouters","year":"2013","journal-title":"Blood"},{"key":"B133","first-page":"2690","article-title":"Peritransfusional C1-inhibitor in patients with severe complement-mediated autoimmune hemolytic anemia: an open-label phase 2 trial. Presented at the European hematology association 2022 congress","volume":"6","author":"de Boer","year":"2022","journal-title":"HemaSphere"},{"key":"B134","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-Human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.HS9.0000561876.96057.48","article-title":"Inhibition of C3 with apl-2 controlshaemolysis and increases haemoglobin levelsin subjects with autoimmune haemolytic anaemia (Aiha)","volume":"3","author":"Gertz","year":"2019","journal-title":"HemaSphere"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0085","article-title":"Sutimlimab for treatment of cold agglutinin disease: why, how and for whom","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.05.001","article-title":"Current treatment options in cold agglutinin disease: b-cell directed or complement directed therapy","volume":"36","author":"Berentsen","year":"2022","journal-title":"Transfus Med Rev"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279812","article-title":"Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: cardinal study 1-year interim follow-up results","volume":"107","author":"R\u00f6th","year":"2022","journal-title":"Haematologica"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2001.00960.x","article-title":"Acute phase haemolysis in chronic cold agglutinin disease","volume":"54","author":"Ulvestad","year":"2001","journal-title":"Scand J Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26409","article-title":"Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery","volume":"97","author":"Tvedt","year":"2022","journal-title":"Am J Hematol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-894303","article-title":"Cold agglutinins: fending off the attack","volume":"133","author":"Berentsen","year":"2019","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159562","article-title":"Sustained complement C1s inhibition with sutimlimab in patients with cold agglutinin disease results in continued efficacy during part b of the randomized placebo-controlled phase 3 cadenza study (Nct03347422)","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.V128.22.1265.1265","article-title":"Anx005, an inhibitory antibody against C1q, blocks complement activation triggered by cold agglutinins in human disease. 58th meeting of the American society of hematology, San Diego, Ca, USA","volume":"128","author":"Gertz","year":"2016","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1177\/1091581817740873","article-title":"Nonclinical development of Anx005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases","volume":"36","author":"Lansita","year":"2017","journal-title":"Int J Toxicol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00281-021-00859-8","article-title":"Halting targeted and collateral damage to red blood cells by the complement system","volume":"43","author":"Jalink","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"Argx-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00004.x","article-title":"Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience","volume":"7","author":"von Baeyer","year":"2003","journal-title":"Ther Apher Dial"},{"key":"B148","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000222800","article-title":"Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery","volume":"20","author":"Zoppi","year":"1993","journal-title":"Infusionsther Transfusionsmed"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-Based approach from the writing committee of the American society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"R\u00f6th","year":"2009","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.18.0532","article-title":"A three year-old boy with back pain, fever and cola-coloured urine","volume":"139","author":"Kvistad","year":"2019","journal-title":"Tidsskr Nor Laegeforen"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2015.01.004","article-title":"Paroxysmal cold hemoglobinuria","volume":"29","author":"Shanbhag","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am J Hematol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04841.x","article-title":"A physician\u2019s guide to transfusion in autoimmune haemolytic anaemia","volume":"124","author":"Petz","year":"2004","journal-title":"Br J Haematol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e18739","DOI":"10.1097\/MD.0000000000018739","article-title":"Autoimmune hemolytic anemia in hospitalized patients: 450 patients and their red blood cell transfusions","volume":"99","author":"Chen","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00583.x","article-title":"\u201cLeast incompatible\u201d units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? a commentary for clinicians and transfusion medicine professionals","volume":"43","author":"Petz","year":"2003","journal-title":"Transfusion"},{"key":"B157","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/hematology.2022000406","article-title":"Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies","volume":"2022","author":"Johnson","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.2450\/2021.0235-21","article-title":"The role of serological and molecular testing in the diagnostics and transfusion treatment of autoimmune haemolytic anaemia","volume":"20","author":"Raos","year":"2022","journal-title":"Blood Transfus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1180509\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T04:24:30Z","timestamp":1682310270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1180509\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":158,"alternative-id":["10.3389\/fimmu.2023.1180509"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1180509","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"article-number":"1180509"}}